StockData
Bioxytran, Inc logo

Bioxytran, Inc (BIXT) stock

BIXTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 0/30
$0.02−0.00 (-3.95%)

Close on Oct 19, 2026Market cap $2.56MP/E –Yield –

Bioxytran net income

Net income is the profit left for shareholders after every expense, interest and tax.

Bioxytran's net income for the twelve months ending Jun 30, 2026 was -$3.49M. For fiscal 2025 it was -$2.12M. The highest annual figure on record is -$296.42K in fiscal 2018.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$2.12M–
FY2024Dec 31, 2024-$2.37M–
FY2023Dec 31, 2023-$4.47M–
FY2022Dec 31, 2022-$2.47M–
FY2021Dec 31, 2021-$4.03M–
FY2020Dec 31, 2020-$2.54M–
FY2019Dec 31, 2019-$1.86M–
FY2018Dec 31, 2018-$296.42K–
FY2017Dec 31, 2017-$318.39K–
FY2016Dec 31, 2016-$696.76K–
FY2015Dec 31, 2015-$2.10M–
FY2014Dec 31, 2014-$1.35M–
FY2013Dec 31, 2013-$1.78M–
FY2012Dec 31, 2012-$2.29M–
FY2011Dec 31, 2011-$4.43M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$619.93K-1849.3%
Q1 FY2026Mar 31, 2026-$2.07M–
Q4 FY2025Dec 31, 2025-$522.16K–
Q3 FY2025Sep 30, 2025-$282.73K–
Q2 FY2025Jun 30, 2025$35.44K–
Q1 FY2025Mar 31, 2025-$1.35M–
Q4 FY2024Dec 31, 2024-$752.14K–
Q3 FY2024Sep 30, 2024-$392.37K–
Q2 FY2024Jun 30, 2024-$661.65K–
Q1 FY2024Mar 31, 2024-$560.52K–
Q4 FY2023Dec 31, 2023-$1.15M–
Q3 FY2023Sep 30, 2023-$1.09M–
Q2 FY2023Jun 30, 2023-$1.45M–
Q1 FY2023Mar 31, 2023-$785.08K–
Q4 FY2022Dec 31, 2022-$814.87K–
Q3 FY2022Sep 30, 2022-$123.64K–
Q2 FY2022Jun 30, 2022-$622.35K–
Q1 FY2022Mar 31, 2022-$912.27K–
Q4 FY2021Dec 31, 2021-$1.04M–
Q3 FY2021Sep 30, 2021-$475.15K–
Q2 FY2021Jun 30, 2021-$896.70K–
Q1 FY2021Mar 31, 2021-$1.62M–
Q4 FY2020Dec 31, 2020-$871.39K–
Q3 FY2020Sep 30, 2020-$202.04K–
Q2 FY2020Jun 30, 2020-$928.60K–
Q1 FY2020Mar 31, 2020-$540.50K–
Q4 FY2019Dec 31, 2019-$662.66K–
Q3 FY2019Sep 30, 2019-$874.12K–
Q2 FY2019Jun 30, 2019-$130.29K–
Q1 FY2019Mar 31, 2019-$191.41K–
Q4 FY2018Dec 31, 2018-$247.95K–
Q3 FY2018Sep 30, 2018-$47.52K-197.2%
Q2 FY2018Jun 30, 2018-$275–
Q1 FY2018Mar 31, 2018-$670–
Q4 FY2017Dec 31, 2017-$86.41K-163.9%
Q3 FY2017Sep 30, 2017$48.88K–
Q2 FY2017Jun 30, 2017-$260.42K–
Q1 FY2017Mar 31, 2017-$64.59K–
Q4 FY2016Dec 31, 2016$135.28K–
Q3 FY2016Sep 30, 2016-$213.99K–

More Bioxytran figures

See a number that looks wrong?